
Communicable E64: Getting micro on macrolides for community-acquired pneumonia
In this episode of Communicable, hosts Emily McDonald and Marc Bonten are joined by Sylvain Lother and Valentijn Schweitzer for a discussion on the use of macrolides in community-acquired pneumonia. T...
4 Loka 50min

Communicable E63: Does oseltamivir harm critically ill patients? The REMAP-CAP results
At the Critical Care Reviews meeting in Belfast in June this year, REMAP-CAP investigators presented results suggesting that oseltamivir may be harmful in critically ill patients with influenza, upend...
20 Syys 1h 3min

Communicable E61: We will make you love PK/PD, part 3
In this episode of Communicable, Amy Legg (Brisbane, Australia), Rekha Pai Mangalore (Melbourne, Australia) & Angela Huttner (Geneva, Switzerland) return for the third part of the ‘We will make you lo...
23 Elo 52min

Communicable E60: Quarterly catch-up (August 2026 edition)
In the second edition of 'Quarterly catch-up', CMI Communications editors Emily McDonald and Erin McCreary round-up the biggest news in infectious diseases and review clinical microbiology and infecti...
9 Elo 49min

Communicable E59: 'Ask me anything' – EUCAST and CLSI leadership explain
In this episode of Communicable, Nav Narayanan and Thomas Tängdén kick off the first 'Ask me anything' episode, inviting EUCAST and CLSI leadership Sören Gatermann, Christian Giske and Amy Mathers to ...
26 Heinä 1h 9min

Communicable E58: Reducing hospital-acquired pneumonia – the HAPPEN trial and how it happened
In this episode of Communicable, Angela Huttner and Josh Davis are joined by Brett Mitchell, Aline Wolfensberger and Lauren Clack to discuss the HAPPEN trial to prevent hospital-acquired pneumonia led...
12 Heinä 54min

Communicable E57: We will make you love PK/PD, part 2
In this episode of Communicable, Thomas Tängdén and Rekha Pai Mangalore return for part 2 of the ‘We will make you love PK/PD’ series. In this round, they are joined by Iris Minichmayr (Austria) and P...
28 Kesä 47min




















